These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22934599)

  • 21. Development and characterization of mouse monoclonal antibodies against monomeric dengue virus non-structural glycoprotein 1 (NS1).
    Gelanew T; Poole-Smith BK; Hunsperger E
    J Virol Methods; 2015 Sep; 222():214-23. PubMed ID: 26070890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics.
    Smith SA; de Alwis R; Kose N; Durbin AP; Whitehead SS; de Silva AM; Crowe JE
    J Infect Dis; 2013 Jun; 207(12):1898-908. PubMed ID: 23526830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of Dengue Virus Serotype-Specific NS1 Capture Assays for the Rapid and Highly Sensitive Identification of the Infecting Serotype in Human Sera.
    Röltgen K; Rose N; Ruggieri A; Warryn L; Scherr N; Pinho-Nascimento CA; Tamborrini M; Jaenisch T; Pluschke G
    J Immunol; 2018 Jun; 200(11):3857-3866. PubMed ID: 29661824
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein.
    Budigi Y; Ong EZ; Robinson LN; Ong LC; Rowley KJ; Winnett A; Tan HC; Hobbie S; Shriver Z; Babcock GJ; Alonso S; Ooi EE
    PLoS Negl Trop Dis; 2018 Feb; 12(2):e0006209. PubMed ID: 29425203
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody Epitopes Identified in Critical Regions of Dengue Virus Nonstructural 1 Protein in Mouse Vaccination and Natural Human Infections.
    Hertz T; Beatty PR; MacMillen Z; Killingbeck SS; Wang C; Harris E
    J Immunol; 2017 May; 198(10):4025-4035. PubMed ID: 28381638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paradoxical Role of Dengue Virus Envelope Protein Domain III Antibodies in Dengue Virus Infection.
    Ali S; Afzal S; Yousaf MZ; Shahid M; Amin I; Idrees M; Aftab A
    Crit Rev Eukaryot Gene Expr; 2020; 30(3):199-206. PubMed ID: 32749106
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection.
    Sasaki T; Setthapramote C; Kurosu T; Nishimura M; Asai A; Omokoko MD; Pipattanaboon C; Pitaksajjakul P; Limkittikul K; Subchareon A; Chaichana P; Okabayashi T; Hirai I; Leaungwutiwong P; Misaki R; Fujiyama K; Ono K; Okuno Y; Ramasoota P; Ikuta K
    Antiviral Res; 2013 Jun; 98(3):423-31. PubMed ID: 23545366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies.
    Gallichotte EN; Widman DG; Yount BL; Wahala WM; Durbin A; Whitehead S; Sariol CA; Crowe JE; de Silva AM; Baric RS
    mBio; 2015 Oct; 6(5):e01461-15. PubMed ID: 26463165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
    Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
    J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genotype-specific neutralization and protection by antibodies against dengue virus type 3.
    Brien JD; Austin SK; Sukupolvi-Petty S; O'Brien KM; Johnson S; Fremont DH; Diamond MS
    J Virol; 2010 Oct; 84(20):10630-43. PubMed ID: 20702644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A highly conserved region between amino acids 221 and 266 of dengue virus non-structural protein 1 is a major epitope region in infected patients.
    Omokoko MD; Pambudi S; Phanthanawiboon S; Masrinoul P; Setthapramote C; Sasaki T; Kuhara M; Ramasoota P; Yamashita A; Hirai I; Ikuta K; Kurosu T
    Am J Trop Med Hyg; 2014 Jul; 91(1):146-55. PubMed ID: 24778195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of two anti-dengue human monoclonal antibodies prepared from PBMCs of patients with dengue illness in Thailand.
    Li ZY; Yamashita A; Kawashita N; Sasaki T; Pan Y; Ono KI; Ikuta K; Li YG
    Acta Virol; 2016 Jun; 60(2):166-73. PubMed ID: 27265466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Generation of Monoclonal Antibodies against Dengue Virus Type 4 and Identification of Enhancing Epitopes on Envelope Protein.
    Tang CT; Liao MY; Chiu CY; Shen WF; Chiu CY; Cheng PC; Chang GJ; Wu HC
    PLoS One; 2015; 10(8):e0136328. PubMed ID: 26309127
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiplexed FluoroSpot for the Analysis of Dengue Virus- and Zika Virus-Specific and Cross-Reactive Memory B Cells.
    Adam A; Woda M; Kounlavouth S; Rothman AL; Jarman RG; Cox JH; Ledgerwood JE; Gromowski GD; Currier JR; Friberg H; Mathew A
    J Immunol; 2018 Dec; 201(12):3804-3814. PubMed ID: 30413671
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.
    Frei JC; Wirchnianski AS; Govero J; Vergnolle O; Dowd KA; Pierson TC; Kielian M; Girvin ME; Diamond MS; Lai JR
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of serotype-specific T cell responses to highly conserved regions of the dengue viruses.
    Malavige GN; McGowan S; Atukorale V; Salimi M; Peelawatta M; Fernando N; Jayaratne SD; Ogg G
    Clin Exp Immunol; 2012 May; 168(2):215-23. PubMed ID: 22471283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection.
    Rivino L; Kumaran EA; Jovanovic V; Nadua K; Teo EW; Pang SW; Teo GH; Gan VC; Lye DC; Leo YS; Hanson BJ; Smith KG; Bertoletti A; Kemeny DM; MacAry PA
    J Virol; 2013 Mar; 87(5):2693-706. PubMed ID: 23255803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection.
    Stettler K; Beltramello M; Espinosa DA; Graham V; Cassotta A; Bianchi S; Vanzetta F; Minola A; Jaconi S; Mele F; Foglierini M; Pedotti M; Simonelli L; Dowall S; Atkinson B; Percivalle E; Simmons CP; Varani L; Blum J; Baldanti F; Cameroni E; Hewson R; Harris E; Lanzavecchia A; Sallusto F; Corti D
    Science; 2016 Aug; 353(6301):823-6. PubMed ID: 27417494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody.
    Wahala WM; Kraus AA; Haymore LB; Accavitti-Loper MA; de Silva AM
    Virology; 2009 Sep; 392(1):103-13. PubMed ID: 19631955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dengue virus antibody database: Systematically linking serotype-specificity with epitope mapping in dengue virus.
    Chaudhury S; Gromowski GD; Ripoll DR; Khavrutskii IV; Desai V; Wallqvist A
    PLoS Negl Trop Dis; 2017 Feb; 11(2):e0005395. PubMed ID: 28222130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.